UK Wearables in Pharma & Biotech Market (2026-2031)
The UK Wearables in Pharma & Biotech Market was valued at $199.5 Million in 2026 and projected to reach to $527.9 Million by 2031, representing a compound annual growth rate of 21.5%. The UK wearables in pharma and biotech market is positioned for sustained growth, with the sector expanding from £157.5 million in 2026 to £417.2 million by 2031 at a 21.5% CAGR.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
UK Wearables in Pharma & Biotech Market Trends and Insights
- The UK market is driven by increasing adoption of remote patient monitoring technologies, regulatory support from the NHS, and growing investment in digital health infrastructure across the country.
- The UK's strong healthcare ecosystem and emphasis on precision medicine are positioning the nation as a key hub for wearable innovation in pharmaceutical and biotech applications. The UK market's 21.5% compound annual growth rate significantly outpaces global trends, reflecting the country's advanced healthcare digitalization and favorable reimbursement policies.
- By 2031, the UK is expected to capture substantial market share within Europe, supported by collaborations between pharmaceutical companies, biotech firms, and wearable technology developers.
- The UK's regulatory framework and NHS integration are accelerating the deployment of wearable devices for clinical trials, patient monitoring, and therapeutic applications..
Key Market Statistics
- CAGR (2026-2031) 21.5% CAGR
- Market Size, 2026 ~USD 199.5 Million
- Forecast, 2031 ~USD 527.9 Million
- Country UK
UK Wearables in Pharma & Biotech Market Overview
NHS Digital Health Integration :
The UK's National Health Service is actively integrating wearable technologies into patient care pathways, creating a structured market opportunity for pharma and biotech companies to deploy remote monitoring solutions across NHS trusts and primary care networks.
Regulatory Clarity & Support :
The UK Medicines and Healthcare products Regulatory Agency (MHRA) provides clear regulatory frameworks for digital health and wearable devices, enabling faster market entry and adoption compared to other regions, fostering innovation in pharma-integrated wearables.
Remote Patient Monitoring Expansion :
Post-pandemic, UK healthcare providers have accelerated remote patient monitoring adoption, with wearables becoming essential for chronic disease management, clinical trials, and real-world evidence generation across cardiovascular, respiratory, and metabolic conditions.
Private & Public Sector Investment :
Significant investment from both NHS England's digital transformation initiatives and private healthcare providers is driving infrastructure development, creating partnerships between biotech firms and UK health systems for wearable-enabled drug delivery and monitoring.
UK Wearables in Pharma & Biotech Market Dynamics
- This expansion is underpinned by NHS digital modernisation programmes, increasing prevalence of chronic diseases, and growing demand for personalised medicine solutions.
- UK biotech companies are leveraging wearable technologies to enhance clinical trial efficiency and generate real-world evidence, attracting both domestic and international investment. The regulatory environment remains favourable, with MHRA guidance supporting innovation in connected devices and digital therapeutics.
- Strategic partnerships between pharmaceutical manufacturers, NHS trusts, and technology providers are accelerating market penetration.
- Additionally, the UK's strong life sciences cluster and government commitment to digital health infrastructure position the country as a leading hub for wearable pharma innovation in Europe, driving competitive advantages and attracting global players to establish UK operations..
Related Ecosystem
Healthcare It
- Computed Tomography (CT)
- Machine Learning
- Magnetic Resonance Imaging (MRI)
- Natural Language Processing (NLP)
- Predictive Analytics
- CERNER CORPORATION
- PHILIPS HEALTHCARE
- Oracle Corporation
- GE HealthCare Technologies Inc.
- Siemens healthineers
Key Takeaways
- The UK wearables in pharma & biotech market is valued at $199.5M in 2026 and will grow to $527.9M by 2031, representing a 21.5% CAGR.
- The UK's NHS integration and regulatory support are key drivers accelerating wearable adoption in pharmaceutical and biotech sectors.
- The UK market growth rate of 21.5% CAGR outpaces global averages, positioning the country as a European leader in digital health innovation.
- The UK's collaborative ecosystem between pharma, biotech, and technology companies is fostering rapid development of wearable solutions for clinical applications.
Wearables in Pharma & Biotech Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2026 |
| Fastest Growing Segment | MENTAL HEALTH & BEHAVIORAL HEALTH (Therapeutic Area) |
| Forecast Period | 2026–2031 |
| Growth Rate | CAGR of 20.2% from 2026 to 2031 |
| Largest Segment | PHARMACEUTICAL & BIOTECH COMPANIES (End User) |
| Market Size Base Year (Billions) | ~USD 3.97 (2026) |
| Revenue Forecast (Billions) | ~USD 9.97 (2031) |
| Segments Covered | Product, Therapeutic Area, Type, Application, End User |
UK Wearables in Pharma & Biotech Market Report Segmentation
5 segment dimensions are covered across the global market.
By Product
- Continuous Glucose Monitors
- Fitness Bands
- Other Products
- Patches
- Smart Rings
- Smartwatches
- Wearable Injectors
By Therapeutic Area
- Cardiovascular
- Diabetes
- Lifestyle & Wellness Improvement
- Mental Health & Behavioral Health
- Musculoskeletal Disorders/Pain Management
- Neurology
- Oncology
- Other Diseases
- Respiratory Disorders
- Women’S Health & Reproductive Health
By Type
- Atherosclerotic Cardiovascular Diseases/Secondary Prevention
- Atrial Fibrillation/Stroke Prevention
- Brain Tumor
- Breast Cancer
- Colorectal Cancer
- Heart Failure
- Hematologic Malignancies
- Hypertension
- Leukemia
- Lung Cancer
- Lymphoma
- Multiple Myeloma
- Other Hematologic Malignancies
- Other Solid Tumors
- Phase Ii
- Phase Iii
- Phase Iv
- Prostate Cancer
- Pulmonary Hypertension
- Solid Tumors
- Structural Heart Diseases/Interventional Cardiology
By Application
- Chronic Disease Monitoring
- Clinical Trials
- Drug Discovery
- Medication Adherence & Behavioral Support
- Personalized & Preventive Digital Therapeutics
By End User
- Contract Research Organizations
- Healthcare Providers & Clinicians
- Other End Users
- Pharmaceutical & Biotech Companies
UK: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024–2031
| Segment | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| CONTRACT RESEARCH ORGANIZATIONS | 47.5 | 57.2 | 69.3 | 84.3 | 103.1 | 126.4 | 155.5 | 191.8 | 22.6 |
| HEALTHCARE PROVIDERS & CLINICIANS | 13.1 | 15.5 | 18.5 | 22.1 | 26.5 | 31.9 | 38.6 | 46.7 | 20.4 |
| OTHER END USERS | 7.2 | 8.4 | 9.9 | 11.6 | 13.7 | 16.1 | 19.1 | 22.6 | 18 |
| PHARMACEUTICAL & BIOTECH COMPANIES | 71.3 | 84.9 | 101.8 | 122.6 | 148.2 | 179.7 | 218.7 | 266.8 | 21.2 |
| TOTAL | 139.1 | 166.1 | 199.5 | 240.6 | 291.5 | 354.2 | 431.9 | 527.9 | 21.5 |
Target Audience
- UK Pharmaceutical Manufacturers : Pharmaceutical companies operating in the UK need market intelligence on wearable integration opportunities, NHS adoption pathways, and competitive positioning to enhance drug efficacy monitoring, patient adherence, and real-world evidence generation for regulatory submissions.
- UK Biotech & Digital Health Startups : Emerging biotech and digital health companies require detailed market sizing, funding landscape analysis, and regulatory guidance specific to the UK to validate business models, secure investment, and accelerate time-to-market for wearable-enabled solutions.
- NHS Trusts & Healthcare Providers : NHS organisations and private healthcare providers need comprehensive market data on wearable technologies, clinical evidence, implementation costs, and vendor capabilities to inform procurement decisions and digital transformation strategy aligned with patient outcomes.
- Medical Device & Wearables Manufacturers : Device manufacturers seeking UK market entry require insights into regulatory pathways, NHS integration requirements, reimbursement models, and competitive dynamics to develop go-to-market strategies and establish partnerships with pharma companies.
- Healthcare Investors & Venture Capital : Investment firms and venture capitalists evaluating UK healthcare opportunities need market forecasts, growth drivers, competitive analysis, and exit opportunities in the wearables pharma sector to make informed funding and acquisition decisions.
Key Companies in the UK Wearables in Pharma & Biotech Market
| Company | HQ | Ownership | Strongest segments |
|---|
Reasons to Buy this Report
- NHS Market Opportunity Identification : Gain detailed insights into NHS procurement pathways, trust-level adoption rates, and integration requirements to position your wearable solutions for large-scale NHS contracts and digital health programmes across England, Scotland, Wales, and Northern Ireland.
- Regulatory & Compliance Roadmap : Access UK-specific MHRA regulatory requirements, CE marking pathways, and data protection compliance frameworks (GDPR, NHS Data Security & Protection Toolkit) essential for launching and scaling wearable devices in the UK pharma market.
- Competitive Landscape & Market Positioning : Understand UK-based competitors, emerging biotech players, and international entrants in the wearables space, enabling strategic positioning, partnership identification, and differentiation strategies tailored to the UK healthcare ecosystem.
- Clinical Trial & Real-World Evidence Insights : Leverage data on UK adoption of wearables in clinical trials, real-world evidence generation, and patient monitoring to optimise trial design, reduce costs, and accelerate drug development timelines within the UK regulatory framework.
- Investment & Partnership Intelligence : Identify funding opportunities, NHS innovation partnerships, venture capital trends, and strategic acquisition targets within the UK wearables ecosystem to inform investment decisions and growth strategies in this high-CAGR market.
Frequently asked questions
What is the current size of the UK wearables in pharma & biotech market?
The UK wearables in pharma & biotech market is estimated at $199.5 million in 2026 and is projected to reach $527.9 million by 2031.
What is the growth rate of the UK wearables market?
The UK market is growing at a compound annual growth rate (CAGR) of 21.5% from 2026 to 2031.
What factors are driving growth in the UK wearables pharma market?
Key drivers include NHS integration, regulatory support, remote patient monitoring adoption, digital health infrastructure investment, and collaborations between pharmaceutical and technology companies in the UK.
How does the UK market compare to global wearables in pharma & biotech growth?
The UK's 21.5% CAGR significantly outpaces the global average of 20.2%, demonstrating the UK's accelerated market expansion and leadership in digital health innovation.
What applications are driving wearable adoption in the UK pharma sector?
The UK market is driven by applications in remote patient monitoring, clinical trials, therapeutic interventions, and precision medicine initiatives supported by the NHS and regulatory bodies.
RESEARCH METHODOLOGY
This study involved five major activities to estimate the current size of the wearables in pharma & biotech market. Exhaustive secondary research was conducted to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Thereafter, market breakdown and data triangulation procedures were used to estimate the market size of the segments and subsegments.
Secondary Research
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to to identify and collect information for the study of the wearables in pharma & biotech market. It was also used to obtain important information about the top players, market classification, and segmentation according to industry trends to the bottom-most level, geographic markets, and key developments related to the market. A database of the key industry leaders was also prepared using secondary research.
Primary Research
Extensive primary research was conducted after acquiring basic knowledge about the global wearables in pharma & biotech market scenario through secondary research. Several primary interviews were conducted with market experts from both the demand side (hospital directors, hospital vice presidents, department heads, and critical care specialists) and supply side (such as C-level and D-level executives, technology experts, product managers, marketing and sales managers, among others) across five major regions: North America, Europe, Asia Pacific, Latin America, the Middle East & Africa. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.
The following is a breakdown of the primary respondents:
Note: Tiers of companies are defined based on their total revenues in 2023. Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = USD 500 million. Other designations include sales managers, marketing managers, and product managers.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the wearables in pharma & biotech market. These methods were also used extensively to estimate the size of various subsegments in the market.
The research methodology used to estimate the market size includes the following:
Wearables in Pharma & Biotech Market : Top-Down and Bottom-Up Approach
Data Triangulation
After arriving at the overall market size using the market size estimation processes, the market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and sub-segment, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the wearables in pharma & biotech market.
Market Definition
The wearables in pharma & biotech market comprise sensor-based, body-worn, or minimally invasive devices and associated digital platforms used to capture continuous physiological and behavioral data across the drug development and healthcare continuum. This includes products such as smartwatches, fitness bands, smart rings, continuous glucose monitors (CGMs), wearable patches, and wearable injectors, which enable real-time monitoring of parameters like heart rate, glucose levels, activity, and treatment adherence. These technologies are applied across a wide range of therapeutic areas, including cardiovascular diseases, oncology (solid tumors and hematologic malignancies), diabetes, mental health, respiratory, neurological, musculoskeletal, and women’s health conditions. The market spans key applications, such as drug discovery, clinical trials (Phase II–IV), medication adherence, chronic disease monitoring, and personalized digital therapeutics, supporting decentralized trials and real-world evidence generation. End users primarily include pharmaceutical and biotechnology companies, healthcare providers, and research organizations, all leveraging wearable technologies to enable data-driven, patient-centric care and more efficient drug development.
Key Stakeholders
- Wearable device & biosensor manufacturers (smartwatches, CGMs, patches, smart rings, wearable injectors)
- Digital health & software platform providers (mobile apps, cloud platforms, AI analytics)
- Component, sensor, & semiconductor technology providers
- Pharmaceutical companies
- Biotechnology companies
- Contract research organizations (CROs)
- Clinical trial sponsors & site management organizations
- Healthcare providers (hospitals, clinics, remote patient monitoring programs)
- Patients & caregivers
- Payers & insurers
- Regulatory & public health authorities (e.g., US Food and Drug Administration, European Medicines Agency)
- Academic institutions & research organizations
- Data management, interoperability & cloud infrastructure providers
- Cybersecurity & data privacy solution providers
- System integrators & IT service providers
- Venture capital & private equity firms
- Investors & financial institutions
- Consulting, regulatory, & compliance service providers
Report Objectives
- To define, describe, and forecast the wearables in pharma & biotech market based on product, therapeutic area, application, end user, and region
- To provide detailed information regarding the major factors (such as drivers, restraints, opportunities, and challenges) influencing market growth
- To strategically analyze micro-markets with respect to individual growth trends, prospects, and contributions to the overall market
- To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To strategically analyze the market structure profile of the key players and comprehensively analyze their core competencies
- To forecast the size of the market segments with respect to five regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
- To track and analyze competitive developments such as product launches and enhancements, investments, partnerships, collaborations, acquisitions, expansions, product approvals, and alliances in the market
Customization Options:
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
Product Analysis
- Product matrix, which gives a detailed comparison of the product portfolios of each company.
Geographic Analysis
- Further breakdown of the Latin America, Europe, and the Middle East & Africa markets into specific countries
Get the Full Wearables in Pharma & Biotech Market Report
Full forecast, segment splits, and company analysis for all Wearables in Pharma & Biotech Market.
- US Wearables in Pharma & Biotech Market
- Canada Wearables in Pharma & Biotech Market
- Germany Wearables in Pharma & Biotech Market
- France Wearables in Pharma & Biotech Market
- Italy Wearables in Pharma & Biotech Market
- Spain Wearables in Pharma & Biotech Market
- China Wearables in Pharma & Biotech Market
- Japan Wearables in Pharma & Biotech Market
- India Wearables in Pharma & Biotech Market
- Australia Wearables in Pharma & Biotech Market
- South Korea Wearables in Pharma & Biotech Market
- Brazil Wearables in Pharma & Biotech Market
- Mexico Wearables in Pharma & Biotech Market
- Saudi Arabia Wearables in Pharma & Biotech Market
- UAE Wearables in Pharma & Biotech Market
- South Africa Wearables in Pharma & Biotech Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report